
Quarterly report 2023-Q2
added 08-02-2023
Conformis EPS Ratio 2011-2025 | CFMS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.99 | -0.36 | -0.34 | -0.44 | -0.74 | -1.24 | -1.39 | -2.6 | -10.8 | -12 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.34 | -12 | -3.69 |
Quarterly EPS Ratio Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.78 | -1.32 | - | -0.08 | -2.15 | -2.24 | - | -0.07 | 0.21 | -0.09 | -0.08 | -0.09 | -0.03 | -0.14 | -0.08 | -0.13 | -0.11 | -0.12 | -0.16 | -0.12 | -0.24 | -0.22 | -0.27 | -0.29 | -0.28 | -0.4 | -0.37 | -0.31 | -0.34 | -0.37 | -0.37 | -0.45 | -2.51 | -3.32 | -2.83 | -2.44 | -2.49 | -3.04 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.21 | -3.32 | -0.809 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
5 | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-2.81 | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | ||
|
Boston Scientific Corporation
BSX
|
1.26 | $ 96.13 | 0.04 % | $ 141 B | ||
|
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
-0.54 | $ 3.6 | - | $ 125 M | ||
|
Cutera
CUTR
|
-2.87 | - | -10.19 % | $ 1.99 M | ||
|
Bio-Rad Laboratories
BIO
|
-25.6 | $ 301.75 | 0.24 % | $ 8.51 B | ||
|
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | ||
|
Eargo
EAR
|
-39.7 | - | - | $ 10.2 M | ||
|
BioSig Technologies
BSGM
|
-0.75 | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
0.76 | $ 48.12 | 0.21 % | $ 7.17 K | ||
|
Abbott Laboratories
ABT
|
7.67 | $ 124.81 | 0.22 % | $ 217 B | ||
|
EDAP TMS S.A.
EDAP
|
-0.51 | $ 2.97 | 4.58 % | $ 111 M | ||
|
InMode Ltd.
INMD
|
2.29 | $ 14.47 | 0.7 % | $ 1.15 B | ||
|
IRIDEX Corporation
IRIX
|
-0.59 | $ 1.14 | 3.64 % | $ 18.4 M | ||
|
IRadimed Corporation
IRMD
|
1.52 | $ 97.06 | 0.48 % | $ 1.23 B | ||
|
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | ||
|
LivaNova PLC
LIVN
|
1.17 | $ 63.08 | -0.27 % | $ 3.42 B | ||
|
LENSAR
LNSR
|
-2.73 | $ 12.01 | -0.08 % | $ 138 M | ||
|
Medigus Ltd.
MDGS
|
0.01 | - | 10.28 % | $ 55.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
-0.17 | $ 9.54 | - | $ 685 M | ||
|
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
5.63 | $ 157.84 | 0.69 % | $ 11.8 B | ||
|
NanoVibronix
NAOV
|
-13.7 | - | - | $ 1.08 M | ||
|
Accuray Incorporated
ARAY
|
-0.02 | $ 0.86 | 0.43 % | $ 88.4 M | ||
|
Myomo
MYO
|
-1.52 | $ 1.02 | 12.09 % | $ 7.19 M | ||
|
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-0.7 | $ 14.49 | 0.84 % | $ 392 M | ||
|
FONAR Corporation
FONR
|
1.78 | $ 14.53 | 0.07 % | $ 95.2 M | ||
|
AxoGen
AXGN
|
-0.23 | $ 32.64 | -0.61 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | ||
|
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
4.29 | $ 40.17 | 1.34 % | $ 1.24 B | ||
|
NuVasive
NUVA
|
0.78 | - | - | $ 2.07 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-1.64 | $ 17.41 | 0.75 % | $ 402 M | ||
|
Globus Medical
GMED
|
0.76 | $ 88.43 | -0.38 % | $ 12 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
-0.09 | $ 12.66 | 0.56 % | $ 975 M |